ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IMV IMV Inc

1.12
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
IMV Inc TSX:IMV Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.12 0.60 0.70 0 01:00:00

Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference

23/04/2018 12:05pm

GlobeNewswire Inc.


IMV (TSX:IMV)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more IMV Charts.

Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada.

Details of the presentation are as follows:

  • Date: Thursday, May 3, 2018
  • Time: 2:30 pm ET
  • Location: Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel, Toronto, Canada

About the Conference Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest development in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings.

About ImmunovaccineImmunovaccine Inc. is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology provides controlled and prolonged exposure to a broad range of immunogenic stimuli. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Company is also exploring additional applications of its platform, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects in malaria and Zika virus. Connect at www.imvaccine.com.

Contacts for Immunovaccine:

MEDIA Mike Beyer, Sam Brown Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com

INVESTOR RELATIONSPierre Labbé, Chief Financial OfficerT: (902) 492-1819 E: info@imvaccine.com

Patti Bank, Managing Director, Westwicke PartnersO: (415) 513-1284T: (415) 515-4572 E: patti.bank@westwicke.com 

1 Year IMV Chart

1 Year IMV Chart

1 Month IMV Chart

1 Month IMV Chart

Your Recent History

Delayed Upgrade Clock